Related Experiment Video
Updated: Jun 28, 2026

A Mass Spectrometry-Based Approach to Identify Phosphoprotein Phosphatases and their Interactors
Published on: April 29, 2022
Identification of PP2A as a novel interactor and regulator of TRIP-Br1
Zhi Jiang Zang1, Lakshman Gunaratnam, Jit Kong Cheong
1Renal Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Abstract:
TRIP-Br proteins are a novel family of transcriptional coregulators involved in E2F-mediated cell cycle progression. Three of the four mammalian members of TRIP-Br family, including TRIP-Br1, are known oncogenes. We now report the identification of the Balpha regulatory subunit of serine/threonine protein phosphatase 2A (PP2A) as a novel TRIP-Br1 interactor, based on an affinity binding assay coupled with mass spectrometry. A GST-TRIP-Br1 fusion protein associates with catalytically active PP2A-ABalphaC holoenzyme in vitro. Coimmunoprecipitation confirms this association in vivo. Immunofluorescence staining with a monoclonal antibody against TRIP-Br1 reveals that endogenous TRIP-Br1 and PP2A-Balpha colocalize mainly in the cytoplasm. Consistently, immunoprecipitation followed by immunodetection with anti-phosphoserine antibody suggest that TRIP-Br1 exists in a serine-phosphorylated form. Inhibition of PP2A activity by okadaic acid or transcriptional silencing of the PP2A catalytic subunit by small interfering RNA results in downregulation of total TRIP-Br1 protein levels but upregulation of serine-phosphorylated TRIP-Br1. Overexpression of PP2A catalytic subunit increases TRIP-Br1 protein levels and TRIP-Br1 co-activated E2F1/DP1 transcription. Our data support a model in which association between PP2A-ABalphaC holoenzyme and TRIP-Br1 in vivo in mammalian cells represents a novel mechanism for regulating the level of TRIP-Br1 protooncoprotein.
Insights
The serine/threonine protein phosphatase 2A (PP2A) Balpha subunit interacts with TRIP-Br1, a proto-oncogene involved in cell cycle regulation. This interaction influences TRIP-Br1 protein levels and phosphorylation, suggesting a novel regulatory mechanism.
Area of Science:
- Molecular Biology
- Cell Biology
- Oncology
Background:
- TRIP-Br proteins are transcriptional coregulators crucial for E2F-mediated cell cycle progression.
- TRIP-Br1, a member of this family, is recognized as a proto-oncogene implicated in cancer development.
Purpose of the Study:
- To identify novel interacting partners of TRIP-Br1.
- To elucidate the functional relationship between TRIP-Br1 and protein phosphatase 2A (PP2A).
Main Methods:
- Affinity binding assay coupled with mass spectrometry to identify TRIP-Br1 interactors.
- GST-TRIP-Br1 fusion protein assays and co-immunoprecipitation to confirm in vitro and in vivo interactions.
- Immunofluorescence microscopy for subcellular localization studies.
- Functional assays involving PP2A inhibition (okadaic acid) and silencing (siRNA), and overexpression studies.
Main Results:
- The Balpha regulatory subunit of PP2A was identified as a novel interactor of TRIP-Br1.
- TRIP-Br1 and PP2A-Balpha colocalize in the cytoplasm, and TRIP-Br1 is serine-phosphorylated.
- PP2A inhibition decreases total TRIP-Br1 but increases its serine-phosphorylated form; PP2A overexpression enhances TRIP-Br1 levels and co-activates E2F1/DP1 transcription.
Conclusions:
- The association between PP2A-ABalphaC holoenzyme and TRIP-Br1 represents a novel mechanism for regulating TRIP-Br1 proto-oncogene levels in mammalian cells.
- PP2A plays a critical role in modulating TRIP-Br1 protein stability and phosphorylation status, impacting its oncogenic function.
More Related Videos
Related Concept Videos
Phosphoinositides and PIPs
Different phosphoinositides are synthesized and recruited on the cytosolic face of the plasma membrane. The localization of specific phosphoinositides concentrated in separate membrane...
Negative Regulator Molecules
IP3/DAG Signaling Pathway
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...

